Predicting the carcinogenic risk of premalignant polyps with fluorescent IGF-1R antibodies can enable individualized treatment for colon polyps, even without tissue sampling and can help avoid unnecessary invasive procedures or repeated treatment. Here, IGF1R is linked to polyp of colon.